Medical Monitor, Clinical Research
Amicus Therapeutics · AmicusTherapeutics
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Medical Monitor, Clinical Research as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:20 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03500094 · Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)Amicus Therapeutics · completed · Fabry Disease
- Ph3NCT02194985 · Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseaseAmicus Therapeutics · completed · Fabry Disease
- Ph1NCT02082327 · A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy VolunteersAmicus Therapeutics · completed · Fabry Disease
- Ph1NCT01853852 · A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese SubjectsAmicus Therapeutics · completed · Fabry Disease · study director
- Ph1NCT01730482 · A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)Amicus Therapeutics · completed · Fabry Disease · study director
- Ph1NCT01730469 · Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal FunctionAmicus Therapeutics · completed · Fabry Disease · study director
- Ph1NCT01489995 · Migalastat Food Effect StudyAmicus Therapeutics · completed · Fabry Disease · study director
- N/ANCT01476163 · Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry DiseaseAmicus Therapeutics · available · Fabry Disease · study director
- Ph3NCT01458119 · Open-Label Phase 3 Long-Term Safety Study of MigalastatAmicus Therapeutics · terminated · Fabry Disease · study director
- Ph3NCT01218659 · Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry DiseaseAmicus Therapeutics · completed · Fabry Disease · study director
- Ph2NCT01196871 · Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry DiseaseAmicus Therapeutics · completed · Fabry Disease
- Ph3NCT00925301 · Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry DiseaseAmicus Therapeutics · completed · Fabry Disease · study director
- Ph2NCT00688597 · Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe DiseaseAmicus Therapeutics · terminated · Pompe Disease
- Ph2NCT00526071 · Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 StudyAmicus Therapeutics · terminated · Fabry Disease · study director
- Ph2NCT00446550 · A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher DiseaseAmicus Therapeutics · completed · Gaucher Disease, Type 1 Gaucher Disease, Gaucher Disease, Type 1 · study director
- Ph2NCT00433147 · A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement TherapyAmicus Therapeutics · completed · Gaucher Disease, Type 1, Type 1 Gaucher Disease, Gaucher Disease · study director
- Ph2NCT00304512 · A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry DiseaseAmicus Therapeutics · completed · Fabry Disease · study director
- Ph2NCT00283933 · A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseAmicus Therapeutics · completed · Fabry Disease · study director
- Ph2NCT00283959 · A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseAmicus Therapeutics · completed · Fabry Disease · study director
- Ph2NCT00214500 · A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseAmicus Therapeutics · completed · Fabry Disease · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.